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A B S T R A C T
Objective: The study aim was to provide an overview of the current evidence available on the link between
chemotherapy (CTX) and fear of cancer recurrence (FoR).
Methods: PubMED, Medline, Embase, PsycINFO and Web of Science databases were searched to identify relevant
studies. Two authors independently selected and assessed the studies regarding eligibility criteria. Meta-analysis
of suitable studies was conducted, and quality rated.
Results: Forty eligible studies were included in the systematic review and twenty-nine of them were included in
further meta-analysis. Meta-analysis of the available data conﬁrmed a weak relationship between CTX and FoR
(29 studies, 30,176 patients, overall r= 0.093, 95% CI: 0.062, 0.123, P ˂ 0.001).
Conclusions: The meta-analysis demonstrates a weak but signiﬁcant relationship between cancer patient's FoR
and the receipt of chemotherapy. However, these results should be interpreted with caution. Further
investigation is warranted to explore possible mechanisms of FoR increase in patients who receive chemother-
apy. Longitudinal studies assessing the trajectory of FoR during chemotherapy are also warranted.
1. Background
Fear of cancer recurrence (FoR) is often deﬁned as ‘fear or worry
that the cancer will return or progress in the same place or a diﬀerent
part of the body’ [1,2]. However, in August 2015, a consensus on a new
deﬁnition of FoR was reached by expert researchers, patient advocates,
and policy makers, that is, 'fear, worry, or concern relating to the
possibility that cancer will come back or progress' [3]. As one of the
most common and aversive psychological phenomenon among cancer
patients, FoR has received growing attention among researchers.
Cancer survivors with high levels of FoR may report negative behaviour
change (e.g. avoidance and excessive personal checking behaviours)
[4], increased health service use [5], diﬃculties making plans for the
future [6] and excessive psychological distress [1,7,8].
A number of studies have investigated factors that are associated
with patient's FoR level. Personal characteristics such as, younger age,
and being female were consistently found to be signiﬁcant predictors of
higher FoR [2,9,10]. However, evidence for other demographic vari-
ables has been mixed. The association between race, educational level,
marital status, employment status, income and FoR was inconsistent
[2,9]. With respect to clinical characteristics, time since cancer
diagnosis was generally unrelated to patient's FoR level, but evidence
for the association between cancer type, disease stage, treatment
modality, physical comorbidity and FoR was still conﬂicted [2,9,10].
There have been several studies focusing on the relationship
between patient's FoR and treatment modality, however the ﬁndings
varied. A previous systematic review by Simard et al. [2] reported a
weak to moderate association between treatment type (surgery/che-
motherapy/radiotherapy) and FoR, and a recent meta-analysis con-
ﬁrmed a weak but signiﬁcant relationship between patient's FoR and
the receipt of radiation treatment [11]. However, several researchers
[12–16] reported heterogeneous results that treatment type was not
related to patients' FoR. Moreover, Llewellyn et al. [17] and Custers
et al. [18] reported that FoR had no association with any socio-
demographic or treatment/clinical variables. Even though many studies
have investigated the link between cancer patient's FoR and the receipt
of chemotherapy (CTX), they failed to demonstrate conclusive ﬁndings.
However, as one of the major types of cancer treatment, studies found
that patients with CTX are at higher risk of getting psychological
problems, such as depression [19] and symptom distress [9]. In
addition, study showed that adverse eﬀects caused by CTX can
contribute to greater FoR [20].
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To date, no study focused solely on the possible association between
FoR and CTX. Therefore, in this study, we aim to conduct a systematic
review and meta-analysis of CTX-FoR-related quantitative studies to
explore the relationship between them. We hope by systematically
summarizing current evidence, an indication of association between
CTX and FoR may be provided. Knowledge of factors associated with
FoR may help to better understand the nature of this fear that is of
substantial importance for further intervention development. Findings
from this study may also help health professionals to identify cancer
patients that are at risk for greater FoR.
2. Method
2.1. Literature search
The study was conducted according to the PRISMA guidelines for a
systematic review and meta-analysis [21]. Five databases, namely,
PubMED, Ovid Medline (1946 to Nov, 2016), Ovid Embase (1974 to
Nov, 2016), PsycINFO (1806 to Nov, 2016) and Web of Science were
searched. The key search terms were: chemo or chemotherapy, cancer
or carcinoma or neoplasm, fear or worry or concern, and recurrence or
progression or relapse or return. The search was performed by two
authors (YY and YW) using the OR and AND functions. The reference
lists of identiﬁed review articles, as well as all included studies, were
also screened manually for any additional relevant studies. No restric-
tions were placed on publication date. Search strategy samples are
outlined in Supplementary Table 1.
2.2. Inclusion and exclusion criteria
In order to be included in the systematic review, references had to
(a) be published in a peer-reviewed journal; (b) be written in English;
(c) include patients who had been treated with CTX (with/without
other treatments) (d) be quantitative studies and report FoR results.
Studies using similar, but not accurate key terms, such as ‘fear of dying’,
‘fear of the worst happening’, ‘fear of the future’, ‘neoadjuvant
treatment’ or ‘chemoradiotherapy’ were excluded. In addition, studies
were excluded if they were commentaries, reviews, dissertations, brief
reports, case studies, conference abstracts, as well as qualitative studies.
Studies were screened for eligibility and codetermined by two inde-
pendent authors (YY and YW). Senior author GH overviewed these
procedures.
2.3. Data extraction
The search identiﬁed potential eligible studies that were subse-
quently more extensively screened for suitability. After removing
duplicate records, titles and abstracts were reviewed and unsuitable
studies were excluded. Then full papers were obtained and examined,
and articles that fulﬁlled the inclusion criteria for the review were
included. For each retained study, the following basic information was
noted: ﬁrst author's name, year of publication, country where the study
was conducted, study design, sample size, and mean age of the
participants. In addition, cancer type, measure of FoR and main
ﬁndings were also recorded.
2.4. Quality assessment
The quality of each included article was assessed using Standard
Quality Assessment Criteria for Quantitative Studies (QualSyst Criteria)
[22]. Items were scored on the speciﬁc criteria (No = 0, Partial = 1,
and Yes = 2). A summary score was calculated for each paper and
deﬁned as limited (score of ˂0.50), adequate (0.50–0.70), good
(0.70–0.80), or strong (˃0.80). Any paper of limited quality was
excluded. The process was performed by two reviewers independently
(YY and YW). In situations of disagreement on the assessment of a
paper, the two reviewers repeated their assessment of the study until
consensus was achieved. The quality assessment table is shown in
Supplementary Table 2.
2.5. Statistical analysis
Upon completion of the systematic review, the programme
Comprehensive Meta-analysis was for quantitative studies was em-
ployed [23]. The eﬀect size was calculated by applying routines to
derive a correlation (r) with accompanying 95% conﬁdence intervals
(CI). The eﬀect size was calculated by r but not Hedges' g because
several of the included studies [20,24–30] had very large sample sizes
(N ˃ 1000), and Hedges' g was more suitable for small-sample studies
[23]. The corresponding authors of articles with incomplete data were
contacted to obtain the required data unavailable in the published
article. Studies for which the corresponding authors could not be
reached were subsequently excluded from the meta-analysis.
Statistical heterogeneity among the papers was reported using the Q
statistic, a P-value < 0.10 or an I-squared value > 50% was consid-
ered as substantial heterogeneity [23]. If substantial heterogeneity was
observed, the correlation would be calculated in accordance with the
random-eﬀects model, otherwise, the results would be calculated based
on the ﬁxed-eﬀects model. The selection of the computational model
was based on the understanding of the underlying distribution. Under
the ﬁxed-eﬀect model we assumed that the true eﬀect size was the same
in all studies, while in the random-eﬀect meta-analysis, we expected the
eﬀect size to be similar but not identical across studies. In other words,
true eﬀect sizes were assumed to be normally distributed under
random-eﬀect model [23].
Subgroup analysis based on the cancer type, year of publication, and
length of scale were performed separately. The ﬁrst analysis aimed to
investigate the potential value of cancer type on the association
between CTX and FoR. All included studies were labeled as the ‘breast
group’, ‘mixed group’, and ‘other cancer group’ respectively because 17
out of 29 (59%) of the included articles focused on breast cancer
patients, 8 (28%) articles focused on mixed cancer patients, and the
remaining 4 (13%) studies focused on testicular (2 articles), pancreatic
(1 article), and head and neck cancer (1 article). The second subgroup
analysis based on the year of study was conducted to investigate the
possible inﬂuence of chemotherapy on fears of cancer recurrence in the
course of time. All included articles were categorized into three groups:
before 2000s, 2000s, and 2010s. The third analysis based on length of
scale was performed to study whether item number of the scales have
an inﬂuence on the CTX-FoR association. Studies were divided into
‘single item’, ‘short’ (< 5 items) and ‘extensive’. Additionally,
Rosenthal's ‘fail safe N’ procedure was adopted to estimate the number
of negative studies that would be required to overturn the total
aggregated result. Funnel plot and Egger's regression intercept test
were also performed in order to assess publication bias.
3. Results
3.1. Characteristics of included studies
The literature search of ﬁve databases identiﬁed 3387 references.
Duplicates were excluded revealing 1156 records. Examination of titles
and abstracts for appropriateness left 128 articles. After retrieving full
texts and further evaluation, 40 studies were identiﬁed and retained.
All of them were then assessed using the QualSyst criteria, and none of
them had the score of limited quality. Therefore, no study was excluded
from the systematic review (quality assessment results are shown in
Table 1). However, 11 studies were excluded from further meta-
analysis because 10 of them failed to report speciﬁc statistic values
[12–16,18,31–34], and one study considered chemotherapy as a
mediator but not an independent predictor of FoR [35]. Finally, 29
articles were included in the meta-analysis. Flowchart of the search
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process is presented in Supplementary Fig. 1.
The cumulative sample size including all studies was 35,200, ranged
from 30 to 10,969. The mean age of patients participating in all studies
varied from 24 to 72.3 years, with ten articles not reporting a median or
mean age. The publication dates of the included articles ranged from
1981 to 2016 (two articles were published in the 1980s, one in the
1990s, fourteen in the 2000s, and the remaining were published since
2010). Twenty-seven studies were conducted in North America, eleven
in Europe, one in Australia and one in Iran. Regarding the FoR
instruments, self-reported questionnaires were used. The number of
scale items ranged from 1 to 42 and nine studies failed to report the
validity/reliability of the measurement. Main characteristics and ﬁnd-
ings of the included publications are presented in Table 2.
3.2. Systematic review
Forty studies were included in the systematic review, and conﬂict-
ing evidence was found among them. Fifteen articles
[4,20,24–26,28,36–44] suggested that having undergone CTX was
signiﬁcantly associated with higher FoR. One [35] reported that having
had CTX is a signiﬁcant mediator of the relationship between age and
FoR (Z =−3.83, P < 0.001). On the contrary, twenty-four studies
[6,10,12–16,18,19,29–34,45–53] suggested that cancer patient's FoR
was not related to CTX, and one study [50], though reported non-
signiﬁcant results, indicated that patients who had received CTX were
less likely to experience high FoR (OR = 0.65, CI: 0.16–2.27).
3.3. Meta-analysis
The meta-analysis statistics derived from the 29 articles consisted of
the following: P-value (ﬁfteen articles [4,20,24,28,30,38,39,
41,42,45,46,51–54]), correlation coeﬃcients (ﬁve articles
[37,40,43,44,47]), odds ratios (ﬁve article [19,25,27,29,50]), B value
(two article, [48,49]), t value (one article, [36]) and means and SDs
(one article, [26]). Heterogeneity test showed that the Q-value of this
study was 68.890, the P-value was< 0.1, and the I-squared value
was> 50% (P-value = 0.000; I-squared = 59.356), hence, substantial
heterogeneity was found and a random-eﬀect model was used. By using
random-eﬀect weights, the summary estimate of the correlation was
0.093 with a 95% conﬁdence interval (CI) of 0.062 to 0.123. The Z-
value was 5.959, and the P-value was< 0.001 (two tailed).
Further subgroup analysis indicated that cancer type, year of
publication and length of scales were all linked to the degree of
association. All subgroups showed a statistically signiﬁcant and positive
correlation (P ˂ 0.001). In the ﬁrst analysis, the correlation value of
‘breast cancer group’ (r= 0.110, CI: 0.073, 0.146) was higher than
‘mixed cancer group’ (r= 0.083, CI: 0036, 0.129) and ‘other cancer
group’ (r= 0.068, CI: 0.000–0.135), however the diﬀerence was not
signiﬁcant (Fig. 1). The second subgroup analysis based on publication
year revealed that the correlation value of ‘before 2000s’ (r= 0.196,
CI: 0.066, 0.319) was higher than ‘2000s’ (r= 0.107, CI: 0.066, 0.148)
and ‘2010s’ (r= 0.079, CI: 0.048, 0.111), however, the diﬀerence was
nonsigniﬁcant, either. The result was also conﬁrmed by ‘Regression of
year on Fisher's Z’ analysis, which showed a nonsigniﬁcant but reducing
trend of the inﬂuence of chemo on recurrence fears (slope =−0.002,
P = 0.115). Regarding the third analysis about scale length, ‘extensive’
group (r= 0.108, CI: 0.070, 0.146) showed greater CTX-FoR associa-
tion than ‘short’ (r= 0.076, CI: 0.023–0.129) and ‘single item’ group
(r= 0.085, CI: 0.034, 0.136). Results of subgroup analysis are shown in
Table 3. Regression plot is outlined in Supplementary Fig. 2.
The fail-safe-N-value, which calculates the number of missing
studies that would bring the P-value to less than the alpha of 1.96
was found to equal 983. This value exceeded Rosenthal's recommended
tolerance value of 5n + 10 (where n is the number of eﬀect sizes) [23],
which suggested that our data were resistant to potential publication
bias. In the examination of the funnel plot, 29 studies were noticeably
distributed symmetrically (funnel plot is showed in Supplementary
Fig. 3). Egger's regression intercept test also showed no statistically
signiﬁcant P-value (intercept = 0.176, SE = 0.502, T= 0.351, and
P = 0.729). Thus, in all, we assume that no apparent publication bias
was found in this review.
4. Discussion
This is the ﬁrst review and meta-analysis to focus speciﬁcally on the
association between CTX and FoR, and the overall results showed a
weak but statistically signiﬁcant correlation between them. Fifteen
studies included in the analysis demonstrated a positive association of
CTX receipt with higher FoR levels. Previous research has shown that
modalities such as radiotherapy are also positively associated with FoR
[11].
There has been a dramatic improvement in the survival of cancer
patients over the last two decades. The use of combined modalities of
treatment, such as surgery, chemotherapy and radiotherapy has
brought great beneﬁts to an expanding patient population. However,
unsurprisingly, the achieved medical success comes at some cost in
terms of patients' functioning level as well as sense of well-being, both
physically and psychologically [33]. As one of the major types of cancer
treatment, CTX may cause adverse eﬀects upon normal body tissue that
may manifest months or even years after treatment completion [33]. In
addition to the possibility of second malignancies developing, CTX may
cause side eﬀects such as, tiredness, nausea and vomiting, loss of hair,
skin and nails, endocrine dysfunction, infertility and later organ
toxicities [55–57]. It has been reported that physical and cognitive
impairments through side eﬀects of cancer treatment can signiﬁcantly
contribute to greater fear of cancer progression (FoP) [20]. More severe
fatigue and symptom burden caused by treatment has also been
conﬁrmed to be associated with higher FoR [14,40]. Therefore, it is
possible that lingering fatigue and physical symptoms may serve as a
reminder of the cancer or be misinterpreted as indicators of cancer
returning, which leads to greater recurrence fears. Also, reports have
shown that living with the eﬀects of CTX could be stressful, frustrating
and traumatic, hence, patients with CTX are at higher risk of getting
psychological and emotional diﬃculties, such as, sleep problems,
depression and anxiety [56]. A number of studies [9,19,58,59] have
reported a moderate positive correlation between FoR and psychologi-
cal morbidity. In particular, generalised anxiety [17], depression [19],
symptom distress [9] and stress [60] has been identiﬁed as strong
predictors of greater distress. Therefore, it is reasonable to conceive
that CTX-related physical symptoms and psychological diﬃculties
contribute to higher FoR.
In contrast, twenty-four studies reported nonsigniﬁcant correlation
between CTX and FoR. One potential explanation is that the inﬂuence
of chemotherapy on FoR may diﬀer depending on whether the
treatment is considered as signalling more serious disease or as
protection against future recurrence [26]. To date, with the advance
of CTX technology, more treatment-relevant information is provided to
patients by health professionals, and chemotherapy is being better
explained before administration [50]. Providing suﬃcient information
assists patients to strengthen their psychosocial adjustment ability, and
to cope better with the side eﬀects. It is possible that with the
improvement of patient-doctor communication and the development
of technology, patients now are more likely to view CTX as a neutral
routine treatment instead of a harmful and fearsome one. This could
also help to explain the reason why there was a decreasing trend
(although not signiﬁcant) of the inﬂuence of chemotherapy on FCR in
the course of time as noted from publication date.
The ﬁndings of the subgroup analysis based on cancer type, showed
that the CTX by FCR association was not statistically signiﬁcant across
the major cancer groups, though the CTX-FoR correlation in ‘breast
group’ was higher than the other two groups, the diﬀerence was not
statistically signiﬁcant. One possible reason why ‘breast group’ showed
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higher correlation value is that patients understand that unlike other
disease which CTX is the only treatment, the administration of
chemotherapy in breast cancer patients usually implies poorer prog-
nosis. Also, a limitation of current FoR-related studies is that the
majority have focused, speciﬁcally, on breast cancer patients [2,9]. In
this review, over half of the studies recruited participants with breast
cancer. Thus it is possible that the inﬂuence of breast cancer studies has
somewhat generated a greater correlation value. Further careful
inspection should be conducted to investigate the potential inﬂuence
of cancer type on the CTX-FoR association. As the analysis based on
scale length, we found no linear association between item number and
the CTX-FoR association value. Correlation in ‘extensive’ group was
higher than the other two groups, but correlation in ‘single-item’ group
was higher than ‘short’ group. Thus in the review, we assume that scale
length has no direct inﬂuence on CTX-FoR correlation.
One study suggested that CTX was a nonsigniﬁcant protective factor
against FoR. This ﬁnding could be a manifestation of the perception
that more aggressive treatment is better at ensuring no cancer
recurrence or progression in the future. However, this ﬁnding should
be interpreted with great caution as this was the only study which
reported such results.
It was not possible to make distinctions in the studies reviewed of
the interaction of CTX type (neo-adjuvant and adjuvant) and FoR as
many of the studies included mixed CTX therapeutic strategies.
Additional investigation where FoR levels are inspected across these
treatment types would further assist our understanding of the associa-
tion. A further mediating variable that has not been included, of course,
is the protocol adopted in each of the specialist units of how to educate
Fig. 1. Random eﬀects meta-analysis of the correlation between CTX and FoR, and subgroup analysis by cancer type. The size of the squares indicates the weight of the study. The
diamond indicates the summary correlation. CI, conﬁdence interval. Deimling1: Deimling et al. (2006a); Deimling2: Deimling et al. (2008); Deimling3: Deimling et al. (2006b); Janz1: Jan
et al. (2011); Lasry1: Lasry (1992); Lasry2: Lasry (1987).
Table 3
results of subgroup analysis.
Analysis Eﬀect size and 95% interval Test of null (2-Tail) Heterogeneity
Groups Number studies Point estimate Lower limit Upper limit Z value P-value Q-value P-value
Group by cancer type
Breast 17 0.110 0.073 0.146 5.794 0.000 Ref
Mixed 8 0.083 0.036 0.129 3.476 0.001 0.800 0.371
Other 4 0.068 0.000 0.135 1.965 0.049 0.785 0.375
Group by year publication
Before 2000s 3 0.196 0.066 0.319 2.937 0.003 Ref
2000s 11 0.107 0.066 0.148 5.042 0.000 1.166 0.280
2010s 15 0.079 0.048 0.111 4.890 0.000 3.320 0.068
Group by length of scale
Single item 6 0.085 0.034 0.136 3.276 0.001 Ref
Short 8 0.076 0.023 0.129 2.791 0.005 0.236 0.627
Extensive 15 0.108 0.070 0.146 5.581 0.000 0.487 0.458
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and inform the patient and carer about the treatment itself. Such
explanations that were oﬀered to patients are likely to inﬂuence their
illness and treatment representations formed during the course of the
care pathways experienced by patients [61].
In all, even though we were able to include a large sample of
participants, this current review has several additional limitations.
First, the majority of the sample was from a white ethnic group.
Therefore, our results may not generalize across other ethnic groups.
Secondly, broad inclusion criteria were used in the meta-analysis,
several included studies used single items or failed to report reliability
details. Also, the publication dates, sample size, age of participants and
item number of the scales of the included studies varied signiﬁcantly,
which may have an inﬂuence on our ﬁnal results. In addition, timing of
chemotherapy was not carefully explored in this study, it is possible
that the CTX-FoR association is weaker in patients who were in post-
chemo phase due to less side eﬀects. However, we failed to analyse this
factor because all included papers did not provide detailed information.
Most importantly, ten studies that reported nonsigniﬁcant CTX-FoR
correlation were excluded from the meta-analysis due to incomplete
data. Therefore, we assume, it is likely that including these studies may
result in a diﬀerent overall association between CTX and FoR. Lastly, no
attempt was made to search for non-English publications or unpub-
lished articles.
5. Conclusion
This systematic review and meta-analysis indicated a weak associa-
tion between patient's fear of cancer recurrence and the receipt of
chemotherapy. The result should be interpreted with caution due to
great variability between studies. The role of chemotherapy side eﬀects
should be speciﬁcally investigated, and further longitudinal studies
should be conducted to assess the trajectory of FoR during chemother-
apy, and the nonsigniﬁcant but decreasing trend of the inﬂuence of CTX
on FoR. The moderators of the association between CTX and FoR should
also be studied closely as they are helpful to identify patients in need.
Psychological interventions focused on psychoeducation, coping skill
building, and meaning ﬁnding should be designed and tested during
CTX as they may likely alleviate FoR development by patients. Of
special signiﬁcance we argue is the underlying beliefs that patients tend
to generate from their contact with their cancer team over the course of
their often protracted and complex treatments. Hence we propose that
illness representations that patients hold become an important focus for
psychological intervention development.
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